Loading…

Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome

It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. To investigate its relationship with the outcome of HCV standard combination therapy with peginterfer...

Full description

Saved in:
Bibliographic Details
Published in:Annals of gastroenterology 2018-01, Vol.31 (5), p.593-597
Main Authors: Mylopoulou, Theodora, Papadopoulos, Vasileios, Kassela, Katerina, Karakasiliotis, Ioannis, Souvalidou, Fani, Mimidis, Panagiotis, Veletza, Stavroula, Mavromara, Penelope, Mimidis, Konstantinos
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c390t-ffcaa71f49d6880cd2da9b132aad459f82a93051caf79008f67e1bc6545e93b03
cites
container_end_page 597
container_issue 5
container_start_page 593
container_title Annals of gastroenterology
container_volume 31
creator Mylopoulou, Theodora
Papadopoulos, Vasileios
Kassela, Katerina
Karakasiliotis, Ioannis
Souvalidou, Fani
Mimidis, Panagiotis
Veletza, Stavroula
Mavromara, Penelope
Mimidis, Konstantinos
description It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. Twenty-nine patients were cirrhotic (stiffness >12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection.
doi_str_mv 10.20524/aog.2018.0290
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6102464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2099042867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-ffcaa71f49d6880cd2da9b132aad459f82a93051caf79008f67e1bc6545e93b03</originalsourceid><addsrcrecordid>eNpVkU1rFTEUhoMotrZuXUqWQrnXk49JJptCubQqFATRRVchkznTG5mZTJNMxX9vrq2lrvJCnvOeAw8h7xhsOTRcfnTxtibWboEbeEGOmTZ8o6USL2tm0Nas2RF5k_NPgEZpKV-TIwFMS2HUMbn5hqMrIc55HxbaYfmFOFM3l9DFPmCmJdI9LhUpIdMdvQ9pzdTHhGeMLikWDAe8pyWhKxPOhca1-DjhKXk1uDHj28f3hPy4uvy--7y5_vrpy-7ieuOFgbIZBu-cZoM0vWpb8D3vnemY4M71sjFDy50R0DDvBm0A2kFpZJ1XjWzQiA7ECTl_6F3WbsLe1xOSG-2SwuTSbxtdsP__zGFvb-O9VQy4VLIWfHgsSPFuxVzsFLLHcXQzxjVbDsaA5K3SFd0-oD7FnBMOT2sY2L8-bPVhDz7swUcdeP_8uCf8nwDxB2A9iOE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2099042867</pqid></control><display><type>article</type><title>Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome</title><source>PubMed Central</source><creator>Mylopoulou, Theodora ; Papadopoulos, Vasileios ; Kassela, Katerina ; Karakasiliotis, Ioannis ; Souvalidou, Fani ; Mimidis, Panagiotis ; Veletza, Stavroula ; Mavromara, Penelope ; Mimidis, Konstantinos</creator><creatorcontrib>Mylopoulou, Theodora ; Papadopoulos, Vasileios ; Kassela, Katerina ; Karakasiliotis, Ioannis ; Souvalidou, Fani ; Mimidis, Panagiotis ; Veletza, Stavroula ; Mavromara, Penelope ; Mimidis, Konstantinos</creatorcontrib><description>It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. Twenty-nine patients were cirrhotic (stiffness &gt;12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection.</description><identifier>ISSN: 1108-7471</identifier><identifier>ISSN: 1792-7463</identifier><identifier>EISSN: 1792-7463</identifier><identifier>DOI: 10.20524/aog.2018.0290</identifier><identifier>PMID: 30174396</identifier><language>eng</language><publisher>Greece: Hellenic Society of Gastroenterology</publisher><subject>Original</subject><ispartof>Annals of gastroenterology, 2018-01, Vol.31 (5), p.593-597</ispartof><rights>Copyright: © Hellenic Society of Gastroenterology 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-ffcaa71f49d6880cd2da9b132aad459f82a93051caf79008f67e1bc6545e93b03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102464/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102464/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30174396$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mylopoulou, Theodora</creatorcontrib><creatorcontrib>Papadopoulos, Vasileios</creatorcontrib><creatorcontrib>Kassela, Katerina</creatorcontrib><creatorcontrib>Karakasiliotis, Ioannis</creatorcontrib><creatorcontrib>Souvalidou, Fani</creatorcontrib><creatorcontrib>Mimidis, Panagiotis</creatorcontrib><creatorcontrib>Veletza, Stavroula</creatorcontrib><creatorcontrib>Mavromara, Penelope</creatorcontrib><creatorcontrib>Mimidis, Konstantinos</creatorcontrib><title>Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome</title><title>Annals of gastroenterology</title><addtitle>Ann Gastroenterol</addtitle><description>It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. Twenty-nine patients were cirrhotic (stiffness &gt;12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection.</description><subject>Original</subject><issn>1108-7471</issn><issn>1792-7463</issn><issn>1792-7463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkU1rFTEUhoMotrZuXUqWQrnXk49JJptCubQqFATRRVchkznTG5mZTJNMxX9vrq2lrvJCnvOeAw8h7xhsOTRcfnTxtibWboEbeEGOmTZ8o6USL2tm0Nas2RF5k_NPgEZpKV-TIwFMS2HUMbn5hqMrIc55HxbaYfmFOFM3l9DFPmCmJdI9LhUpIdMdvQ9pzdTHhGeMLikWDAe8pyWhKxPOhca1-DjhKXk1uDHj28f3hPy4uvy--7y5_vrpy-7ieuOFgbIZBu-cZoM0vWpb8D3vnemY4M71sjFDy50R0DDvBm0A2kFpZJ1XjWzQiA7ECTl_6F3WbsLe1xOSG-2SwuTSbxtdsP__zGFvb-O9VQy4VLIWfHgsSPFuxVzsFLLHcXQzxjVbDsaA5K3SFd0-oD7FnBMOT2sY2L8-bPVhDz7swUcdeP_8uCf8nwDxB2A9iOE</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Mylopoulou, Theodora</creator><creator>Papadopoulos, Vasileios</creator><creator>Kassela, Katerina</creator><creator>Karakasiliotis, Ioannis</creator><creator>Souvalidou, Fani</creator><creator>Mimidis, Panagiotis</creator><creator>Veletza, Stavroula</creator><creator>Mavromara, Penelope</creator><creator>Mimidis, Konstantinos</creator><general>Hellenic Society of Gastroenterology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180101</creationdate><title>Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome</title><author>Mylopoulou, Theodora ; Papadopoulos, Vasileios ; Kassela, Katerina ; Karakasiliotis, Ioannis ; Souvalidou, Fani ; Mimidis, Panagiotis ; Veletza, Stavroula ; Mavromara, Penelope ; Mimidis, Konstantinos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-ffcaa71f49d6880cd2da9b132aad459f82a93051caf79008f67e1bc6545e93b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mylopoulou, Theodora</creatorcontrib><creatorcontrib>Papadopoulos, Vasileios</creatorcontrib><creatorcontrib>Kassela, Katerina</creatorcontrib><creatorcontrib>Karakasiliotis, Ioannis</creatorcontrib><creatorcontrib>Souvalidou, Fani</creatorcontrib><creatorcontrib>Mimidis, Panagiotis</creatorcontrib><creatorcontrib>Veletza, Stavroula</creatorcontrib><creatorcontrib>Mavromara, Penelope</creatorcontrib><creatorcontrib>Mimidis, Konstantinos</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mylopoulou, Theodora</au><au>Papadopoulos, Vasileios</au><au>Kassela, Katerina</au><au>Karakasiliotis, Ioannis</au><au>Souvalidou, Fani</au><au>Mimidis, Panagiotis</au><au>Veletza, Stavroula</au><au>Mavromara, Penelope</au><au>Mimidis, Konstantinos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome</atitle><jtitle>Annals of gastroenterology</jtitle><addtitle>Ann Gastroenterol</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>31</volume><issue>5</issue><spage>593</spage><epage>597</epage><pages>593-597</pages><issn>1108-7471</issn><issn>1792-7463</issn><eissn>1792-7463</eissn><abstract>It has been suggested that hepatitis C virus (HCV) core+1 protein plays a crucial role in the viral life cycle, potentially affecting liver cirrhosis and the development of hepatocellular carcinoma. To investigate its relationship with the outcome of HCV standard combination therapy with peginterferon-α plus ribavirin, we screened 139 consecutive HCV patients (119 with chronic HCV infection and 20 who spontaneously cleared HCV) for the presence of anti-core+1 antibodies (Abs). In addition, liver fibrosis was determined by FibroScan in all but one patients. Twenty-nine patients were cirrhotic (stiffness &gt;12.5 kPa, F4 METAVIR), all of them with mild liver cirrhosis (Child-Pugh score A). Eighty-six of 139 patients were treatment-experienced with standard combination therapy. Fifty of them had achieved a sustained virological response, while 36 were non-responders. The prevalence of anti-core+1 Abs in patients with chronic HCV infection was 22.69% (27/119 patients): 18% (9/50 patients) in responders and 36.11% (13/36 patients) in non-responders (P=0.050). Five (17.24%) of the 29 cirrhotic patients and 22 (24.72%) of the 89 non-cirrhotic patients were positive for anti-core+1 Abs (P=0.405). Furthermore, the presence of anti-core+1 Abs correlated with the poor response interleukin (IL) 28B genotype TT (P=0.040). No correlation between spontaneous clearance and anti-core+1 Abs was observed (P=0.088). The presence of anti-core+1 Abs might be correlated with the poor response IL28B TT genotype and may negatively affect the outcome of standard combination treatments in HCV patients, suggesting that core+1 may play a biological role in the course of HCV infection.</abstract><cop>Greece</cop><pub>Hellenic Society of Gastroenterology</pub><pmid>30174396</pmid><doi>10.20524/aog.2018.0290</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1108-7471
ispartof Annals of gastroenterology, 2018-01, Vol.31 (5), p.593-597
issn 1108-7471
1792-7463
1792-7463
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6102464
source PubMed Central
subjects Original
title Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A18%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20antibodies%20to%20hepatitis%20C%20virus%20core+1%20protein%20and%20treatment%20outcome&rft.jtitle=Annals%20of%20gastroenterology&rft.au=Mylopoulou,%20Theodora&rft.date=2018-01-01&rft.volume=31&rft.issue=5&rft.spage=593&rft.epage=597&rft.pages=593-597&rft.issn=1108-7471&rft.eissn=1792-7463&rft_id=info:doi/10.20524/aog.2018.0290&rft_dat=%3Cproquest_pubme%3E2099042867%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-ffcaa71f49d6880cd2da9b132aad459f82a93051caf79008f67e1bc6545e93b03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2099042867&rft_id=info:pmid/30174396&rfr_iscdi=true